Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BCL3 | P20749 | 5/20 | 0.41 |
| ▸ | CNR1 | P21554 | 2/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.38 |
| ▸ | MC4R | P32245 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.37 |
| ▸ | CNR2 | P34972 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.37 |
| ▸ | ABCB1 | P08183 | 2/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13147008 | 0.87 | TDP1 (0.40) | BCL3CNR1SMN1; SMN2NPC1TP53 | |
| SCHEMBL13146966 | 0.82 | MC4R (0.54) | MC4RALDH1A1 | |
| SCHEMBL3080769 | 0.73 | ALDH1A1 (0.52) | BCL3CNR1SMN1; SMN2NPSR1MC4R | |
| SCHEMBL3080771 | 0.72 | MC4R (0.57) | CNR1NPSR1MC4RCNR2ALDH1A1 | |
| SCHEMBL3095690 | 0.65 | KDM4E (0.48) | BCL3MC4RALDH1A1 | |
| SCHEMBL13180382 | 0.64 | MC4R (0.40) | NPC1RAB9AMC4RALDH1A1 | |
| SCHEMBL3095697 | 0.64 | MC4R (0.65) | MC4R | |
| SCHEMBL3082128 | 0.64 | MCL1 (0.54) | SMN1; SMN2MC4RTDP1LMNA | |
| SCHEMBL13724364 | 0.64 | MC4R (0.32) | BCL3NPC1RAB9AMC4RALDH1A1 | |
| SCHEMBL3093429 | 0.64 | MC4R (0.54) | SMN1; SMN2MC4R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| US-7790719-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS, INC. (US) | 2010-09-07 | — | — | US | disclosed |
| EP-1590338-B1 | MODULATORS OF MELANOCORTIN RECEPTOR | ORE PHARMACEUTICALS INC (US) | 2009-08-26 | — | — | EP | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-7365070-B2 | Modulators of melanocortin receptor | ORE PHARMACEUTICALS INC. (US) | 2008-04-29 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
| US-20070293498-A1 | Modulators of melanocortin receptor | GENE LOGIC, INC. (US) | 2007-12-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070293498-A1 | Modulators of melanocortin receptor | MC4R, MC1R, MC5R | BCL3 1635/4885CNR1 63/4885SMN1; SMN2 1777/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.